CLDX - セルデックス・セラピュ―ティクス (Celldex Therapeutics Inc.) セルデックス・セラピュ―ティクス

 CLDXのチャート


 CLDXの企業情報

symbol CLDx
会社名 Celldex Therapeutics Inc. (セルデックス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 セルデックス・セラピューティクス(Celldex Therapeutics Inc.)はバイオ医薬品会社である。同社はがんおよび他の疾患の治療のためのいくつかの免疫療法技術の開発・商業化に従事する。主薬のリンテカ(リンドペピムートおよびCDX-110とも呼ばれる)は、神経膠芽腫患者の治療のための治療的ワクチンである。そのグレムバツムマブベドチン(CDX-011とも呼ばれる)は、転移性メラノーマの治療のためのものである。バリルマブ(CDX-1127とも呼ばれる)は、免疫調節抗体である。臨床開発における早期段階の薬剤候補には、癌の適応症のための抗原提示細胞(APC)および免疫細胞動員剤および樹状細胞増殖因子であるCDX-301を標的とする標的免疫療法剤であるCDX-1401が含まれる。同社は多面的腫瘍関連マクロファージ(TAM)プログラムを含む。同社のパイプラインには、ヒト化モノクローナル抗体であるCDX-0158とCDX-3379を含む。   セルデックス・セラピュ―ティクスは、米国のバイオ医薬品企業。癌および治療が困難な疾患のための免疫療法技術の開発と商業化に従事する。薬剤候補は、「Rindopepimut(CDX-110)」免疫療法に標的を当てる、「Glembatumumab vedotin (CDX-011)」トリプルネガティブ乳癌治療のための薬などがある。   Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
本社所在地 Perryville III Building 53 Frontage Road Suite 220 Hampton NJ 08827 USA
代表者氏名 Larry Ellberger ラリー・エルバーガー
代表者役職名 Independent Chairman of the Board
電話番号 +1 908-200-7500
設立年月日 30651
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 197人
url www.celldex.com
nasdaq_url https://www.nasdaq.com/symbol/cldx
adr_tso
EBITDA EBITDA(百万ドル) -66.64400
終値(lastsale) 0.4326
時価総額(marketcap) 70272552.8232
時価総額 時価総額(百万ドル) 67.41357
売上高 売上高(百万ドル) 14.21100
企業価値(EV) 企業価値(EV)(百万ドル) -46.59543
当期純利益 当期純利益(百万ドル) -183.84300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Celldex Therapeutics Inc. revenues increased 27% to $6.8M. Net loss increased from $62.8M to $134.5M. Revenues reflect Revenue Sales of Goods_Services increase from $1.3M to $2.7M Contracts and Grants increase of 1% to $4.2M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.51 to -$0.95.

 CLDXのテクニカル分析


 CLDXのニュース

   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Celldex (CLDX) Down 3.9% Since Last Earnings Report: Can It Rebound?  2019/12/12 16:30:19 Zacks Investment Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159  2019/11/18 13:01:00 Yahoo Finance
Celldex Therapeutics, Inc. (CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety
   The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight  2019/11/03 15:51:51 Benzinga
Biotech stocks extended their gains last week amid earnings news flow and the broader market strength. Large-cap pharma stocks saw particular strength. Here are the key catalytic event a biotech investor should keep a tab on in the unfolding week. Conferences American Society of Nephrology Kidney Week – Nov. 5-10, in Washington D.C. Wolfe Research Healthcare Conference – Nov. 6, in New York Society for Immunotherapy of Cancer, or SITC, – Nov. 6-10, in National Harbor, Maryland PDUFA Dates The FDA is set to rule on Lipocine Inc (NASDAQ: LPCN )'s NDA for Tlando, or LPCN 1021 to treat hypogonadism in adult males. The PDUFA date is set for Saturday, Nov. 9. Clinical Trial Readouts SITC Presentations Alkermes Plc (NASDAQ: ALKS ) – Phase 1/2 data for ALKS 4230 in solid tumors and ALKS 4230 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in solid tumors. Celldex Therapeutics, Inc. (NASDAQ: CLDX ) – Phase 1 data for CDX-1140 in solid tumors (Thursday, Nov. 7). Pieris Pharmaceuticals Inc (NASDAQ: PIRS ) – Phase 1/2 data for PRS-343 in HER2-positive solid tumors.
   Will Celldex Therapeutics (CLDX) Report Negative Q3 Earnings? What You Should Know  2019/10/30 14:33:45 Zacks Investment Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Celldex misses by $0.26, beats on revenue  2019-05-07
Celldex (NASDAQ: CLDX ): Q1 GAAP EPS of -$1.40 misses by $0.26 . More news on: Celldex Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …
   Oncology players in the red on Celgene deal  2019-01-03
A wide range of oncology companies are under modest pressure after deal-hungry Bristol-Myers Squibb announced its $74B bid for Celgene, thereby removing a top candidate from the list of potential suitors. More news on: NewLink Genetics Corporation, Corvus Pharmaceuticals, Nektar Therapeuti…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セルデックス・セラピュ―ティクス CLDX Celldex Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)